The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Amyloid β‐peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease
Abstract
The extracellular accumulation of amyloid‐beta (Aβ) in neuritic plaques is one of the characteristic hallmarks of Alzheimer's disease (AD), a progressive dementing neurodegenerative disorder of the elderly. By virtue of its structure, Aβ is able to bind to a variety of biomolecules, including lipids, proteins and proteoglycans. The binding of the various forms of Aβ (soluble or fibrillar) to plasma membranes has been studied with regard to the direct toxicity of Aβ to neurons, and the activation of a local inflammation phase involving microglia. The binding of Aβ to membrane lipids facilitates Aβ fibrillation, which in turn disturbs the structure and function of the membranes, such as membrane fluidity or the formation of ion channels. A subset of membrane proteins binds Aβ. The serpin‐enzyme complex receptor (SEC‐R) and the insulin receptor can bind the monomeric form of Aβ. The α7nicotinic acetylcholine receptor (α7nAChR), integrins, RAGE (receptor for advanced glycosylation end‐products) and FPRL1 (formyl peptide receptor‐like 1) are able to bind the monomeric and fibrillar forms of Aβ. In addition, APP (amyloid precursor protein), the NMDA‐R (N‐methyl‐D‐aspartate receptor), the P75 neurotrophin receptor (P75NTR), the CLAC‐P/collagen type XXV (collagen‐like Alzheimer amyloid plaque component precursor/collagen XXV), the scavenger receptors A, BI (SR‐A, SR‐BI) and CD36, a complex involving CD36, α 6 β 1–integrin and CD47 have been reported to bind the fibrillar form of Aβ. Heparan sulfate proteoglycans have also been described as cell‐surface binding sites for Aβ. The various effects of Aβ binding to these membrane molecules are discussed. Copyright © 2004 European Peptide Society and John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Protein misfolding, evolution and disease
Dobson, C. M. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01445-0 · Cited by 1,952
Statins and the risk of dementia
Jick, H., Zornberg, G., Jick, S., Seshadri, S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,759
Stefani, M., & Dobson, C. M. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0464-5 · Cited by 1,651
The human insulin receptor cDNA: The structural basis for hormone-activated transmembrane signalling
Ebina, Y., Ellis, L., Jarnagin, K., Edery, M., Graf, L., Clauser, E., Ou, J.-H., Masiarz, F., Kan, Y. W., Goldfine, I. D., et al. (1985) · Cell · doi:10.1016/0092-8674(85)90334-4 · Cited by 1,477
Cited by
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
Astrocytes are active players in cerebral innate immunity
Farina, C., Aloisi, F., & Meinl, E. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.01.005 · Cited by 1,304
Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954
A network dysfunction perspective on neurodegenerative diseases
Palop, J. J., Chin, J., & Mucke, L. (2006) · Nature · doi:10.1038/nature05289 · Cited by 692
Metadata
- Authors
- Verdier, Y., Zarándi, M., & Penke, B.
- Venue
- Journal of Peptide Science
- Publisher
- Wiley
- Published
- 2004-04-26
- Volume
- 10
- Issue
- 5
- Pages
- 229-248
- ISSN
- 1075-2617 (ISSN-L)
- 1099-1387
- OpenAlex
- W2029651181
- Cited by
- 262
- References
- 143
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amyloid β‐peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. https://app.cochat.ai/papers/10.1002/psc.573
- The paper
- Verdier, Y., Zarándi, M., & Penke, B. (2004). Amyloid β‐peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. Journal of Peptide Science. https://doi.org/10.1002/psc.573
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.